SCHEMBL2179155

SCHEMBL2179155

COc1cc(NC(=O)CCN)cc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
MTNR1B P49286 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
CDYL Q9Y232 1/20 0.46
MAPT P10636 4/20 0.45
THRB P10828 1/20 0.45
TSHR P16473 1/20 0.45
ANO1 Q5XXA6 1/20 0.45
ANO2 Q9NQ90 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44
PSMD14 O00487 1/20 0.44
MMP2 P08253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9185732 0.90 ALDH1A1 (0.52) KDM4EALDH1A1NPSR1RXFP1NPC1
SCHEMBL14544643 0.85 MAPT (0.48) KDM4EALDH1A1NPSR1RXFP1MTNR1B
SCHEMBL6820161 0.84 LTA4H (0.55) KDM4EALDH1A1NPSR1RXFP1NPC1
SCHEMBL6820163 0.84 LTA4H (0.55) KDM4EALDH1A1NPSR1RXFP1NPC1
SCHEMBL7715008 0.84 LTA4H (0.55) KDM4EALDH1A1NPSR1RXFP1NPC1
SCHEMBL14521459 0.82 MAPT (0.46) KDM4EALDH1A1NPSR1RXFP1NPC1
SCHEMBL7738208 0.78 TAAR1 (0.48) KDM4EALDH1A1NPSR1RXFP1NPC1
SCHEMBL6055173 0.78 ATM (0.63) KDM4ENPC1RAB9AMEN1KMT2A
SCHEMBL6281901 0.78 IDO1 (0.47) KDM4EALDH1A1NPSR1RXFP1NPC1
Benzene SCHEMBL6822148 0.78 MMP2 (0.47) KDM4EALDH1A1NPSR1RXFP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050282872-A1 Novel thyroid receptor ligands and method II HANGELAND JON 2005-12-22 US claimed
EP-2631238-A1 Spirocyclic inhibitors of serine proteases for the treatment of hcv infections VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-28 EP disclosed
US-8440706-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-14 US disclosed
EP-1917269-B1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMA (US) 2011-10-26 EP disclosed
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES PRSS1, PRSS3, PRSS2 KDM4E 2603/4885ALDH1A1 1374/4885NPSR1 1382/4885
US-20050282872-A1 Novel thyroid receptor ligands and method II TSHR, THRB, THRA KDM4E 3918/4885ALDH1A1 2107/4885NPSR1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.